Equities research analysts predict that DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) will report earnings of ($0.17) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for DelMar Pharmaceuticals’ earnings. DelMar Pharmaceuticals reported earnings of ($0.23) per share in the same quarter last year, which would indicate a positive year over year growth rate of 26.1%. The firm is expected to issue its next quarterly earnings results on Thursday, November 9th.

On average, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.61) per share for the current year, with EPS estimates ranging from ($0.65) to ($0.57). For the next year, analysts anticipate that the business will post earnings of ($0.26) per share. Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for DelMar Pharmaceuticals.

DMPI has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of DelMar Pharmaceuticals in a report on Thursday, October 5th. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.

Shares of DelMar Pharmaceuticals (DMPI) traded down 1.8184% during midday trading on Friday, hitting $0.8639. The company’s stock had a trading volume of 369,232 shares. The firm’s market cap is $18.62 million. DelMar Pharmaceuticals has a 52-week low of $0.80 and a 52-week high of $5.70. The stock’s 50 day moving average is $1.01 and its 200-day moving average is $1.92.

TRADEMARK VIOLATION WARNING: “DelMar Pharmaceuticals, Inc. (DMPI) Expected to Announce Earnings of -$0.17 Per Share” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/22/delmar-pharmaceuticals-inc-dmpi-expected-to-announce-earnings-of-0-17-per-share.html.

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Franklin Resources Inc. bought a new position in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 8.64% of the stock is currently owned by institutional investors.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.